Thursday, February 11, 2021 7:56:49 AM
Good to see another familiar face back at the scene of the crime that we all witnessed. Again, I ask anyone who claims to “know about this company: what specifically is different NOW that they couldn’t do 3 years ago (let’s not forget that, as an alternative therapeutics company, they benefitted from “Right to Try” legislation a couple years back—what RESULTS directly relatable to PPS did they “deliver” to shareholders, as they claimed in October 2019, now that we are approaching 1.5 years AFTER that declaration?). And more basically, what are the specific revenue streams and activity channels that make up the BUSINESS PLAN? None of their PRs has ever addressed these fundamental business questions. Therefore I remain skeptical (hopeful but skeptical—since HOPE is not a STRATEGY, in business or anywhere else in life).
Recent CELZ News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/20/2026 08:45:28 PM
- Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline • GlobeNewswire Inc. • 02/10/2026 02:00:00 PM
- Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain • GlobeNewswire Inc. • 01/13/2026 02:15:00 PM
- Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative • GlobeNewswire Inc. • 01/06/2026 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/31/2025 09:05:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2025 09:01:58 PM
- Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point • GlobeNewswire Inc. • 12/17/2025 02:15:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/16/2025 09:05:24 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/15/2025 05:15:26 AM
- Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201 • GlobeNewswire Inc. • 12/02/2025 02:15:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/21/2025 09:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 11:12:58 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2025 09:46:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 08:05:42 PM
- Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits • GlobeNewswire Inc. • 10/30/2025 01:15:00 PM
- Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds • GlobeNewswire Inc. • 10/29/2025 01:00:00 PM
- Creative Medical Technology Holdings Issues Letter to Shareholders • GlobeNewswire Inc. • 10/27/2025 12:15:00 PM
- Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs • GlobeNewswire Inc. • 10/07/2025 01:15:00 PM
- Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain • GlobeNewswire Inc. • 08/13/2025 01:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2025 08:45:55 PM
- Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells • GlobeNewswire Inc. • 07/17/2025 01:15:00 PM
